Transcription of AUSTRALIAN PRODUCT INFORMATION ... - …
{{id}} {{{paragraph}}}
Example: biology
AUSTRALIAN PRODUCT INFORMATION ... - …
This medicinal PRODUCT is subject to additional monitoring in Australia. This will allow quick identification of new safety INFORMATION . Healthcare professionals are asked to report any suspected adverse events at AUSTRALIAN PRODUCT INFORMATION . CABOMETYX (CABOZANTINIB) TABLETS 20, 40 AND 60MG. 1 NAME OF THE MEDICINE. Cabozantinib (S)-malate 2 QUALITATIVE AND QUANTITATIVE COMPOSITION. CABOMETYX tablets contain cabozantinib(S)-malate equivalent to either 20 mg, 40 mg or 60 mg of cabozantinib as the active ingredient. Cabozantinib (S)-malate is a white to off-white, non-hygroscopic, crystalline substance. It is practically insoluble above pH of 4 and in water. For the full list of excipients, see section LIST OF EXCIPIENTS.
CABOMETYX Product Information V1.0 3 Patients with renal impairment Cabozantinib should be used with caution in patients with mild or moderate renal
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Related search queries
CLOFEN, Impairment, NIH Stroke Scale, Age Associated Cognitive Decline and Mild, To Work after a Concussion or, Auditory Scanning, Divisions for Special Education Services and, Divisions for Special Education Services and Supports, Assistive Technology for Students, Assistive Technology for Students who, Diagnostic Criteria for Persistent, Diagnostic Criteria for Persistent Postural‐Perceptual